GPT and HELLP syndrome: Data generated in the past 2 decades suggest that the CORT treatment to HELLP patients is associated with improvements in biological markers including platelet count, serum aspartate aminotransaminase (AST), alanine transaminase (ALT), and lactic dehydrogenase (LDH) levels, without affecting overall morbidity and mortality.6,7 It is important to know which factors can affect the efficacy of CORT in improving HELLP syndrome markers to identify subgroups of patients that can be benefitted with CORT treatment.